CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) — Market Cap & Net Worth
Market Cap & Net Worth: CAMP4 THERAPEUTICS CORPORATION (CAMP)
CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) has a market capitalization of $218.09 Million ($218.09 Million) as of June 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16294 globally and #3808 in its home market, demonstrating a -0.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CAMP4 THERAPEUTICS CORPORATION's stock price $4.20 by its total outstanding shares 51925800 (51.93 Million). Review CAMP liabilities breakdown to assess the company's total debt and financial obligations.
CAMP4 THERAPEUTICS CORPORATION Market Cap History: 2024 to 2026
CAMP4 THERAPEUTICS CORPORATION's market capitalization history from 2024 to 2026. Data shows change from $271.05 Million to $218.09 Million (-42.45% CAGR).
Index Memberships
CAMP4 THERAPEUTICS CORPORATION is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #446 of 976 |
|
NASDAQ Composite
IXIC
|
$40.53 Trillion | 0.00% | #1596 of 3165 |
Weight: CAMP4 THERAPEUTICS CORPORATION's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CAMP4 THERAPEUTICS CORPORATION Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CAMP4 THERAPEUTICS CORPORATION's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
91.00x
CAMP4 THERAPEUTICS CORPORATION's market cap is 91.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $271.05 Million | $652.00K | -$51.79 Million | 415.72x | N/A |
| 2025 | $318.31 Million | $3.50 Million | -$80.40 Million | 91.00x | N/A |
Competitor Companies of CAMP by Market Capitalization
Companies near CAMP4 THERAPEUTICS CORPORATION in the global market cap rankings as of June 24, 2026.
Key companies related to CAMP4 THERAPEUTICS CORPORATION by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $63.10 Billion USD.
- UCB SA (BR:UCB): Ranked #546 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $466.79 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.10 Billion | $612.50 |
| #546 | UCB SA | BR:UCB | $49.68 Billion | €247.60 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €796.00 |
CAMP4 THERAPEUTICS CORPORATION Historical Marketcap From 2024 to 2026
Between 2024 and today, CAMP4 THERAPEUTICS CORPORATION's market cap moved from $271.05 Million to $ 218.09 Million, with a yearly change of -42.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $218.09 Million | -31.48% |
| 2025 | $318.31 Million | +17.43% |
| 2024 | $271.05 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 23rd, 2026 the market cap of CAMP4 THERAPEUTICS CORPORATION was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $218.09 Million USD |
| MoneyControl | $218.09 Million USD |
| MarketWatch | $218.09 Million USD |
| marketcap.company | $218.09 Million USD |
| Reuters | $218.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more